Home / Research and Innovation

Research and Innovation at Amoytop Biotech

Since its establishment, Amoytop Biotech has been focusing on recombinant protein medicines and their long-acting modification. After continuous building and improving its R&D team and R&D system, Amoytop Biotech’s functional modules, including R&D Center, Medical Development Center, Manufacturing Center and Quality Center, are able to cover every step in the R&D of innovative drugs, from scientific discovery, laboratory trial, pilot trial, preclinical and clinical trial to industrialization.

Research and Innovation

Insisting on constant innovation and development, Amoytop Biotech has built up a research and development team for therapeutic recombinant proteins and relevant long-acting modified innovative drugs, which was selected as the "Innovation Team in Priority Fields" of the Ministry of Science and Technology. Since the 11^th five-year plan, this team has undertaken nine projects of Significant New Drugs Development, which are National Major Scientific and Technological Special Projects; The team has been participating in three sub-projects under the National Science and Technology Major Project for Innovative Drug Development, securing seven Class 1 new drugs either already launched or currently in clinical trials.

Amoytop Biotech owns a professional research and development center—Xiamen Biosteed Gene Transformation Tech. Co., Ltd. Meanwhile, it has established a postdoctoral research station and national-local joint research center, possessing sufficient talent reserves to make breakthroughs in core technologies.
- R&D team for therapeutic recombinant proteins and relevant long-acting modified innovative drugs
- R&D team for therapeutic recombinant proteins and relevant long-acting modified innovative drugs
- R&D team for therapeutic recombinant proteins and relevant long-acting modified innovative drugs
- Research and Innovation about Amoytop Biotech
- Research and Innovation about Amoytop Biotech

Main Pipelines

Focusing on the treatment of major diseases and the development of innovative protein drugs to meet clinical treatment request, especially for viral hepatitis, malignant tumors and immune diseases, Amoytop Biotech has established a comprehensive research and development system to ensure sustainable development in new drug R&D field.

WELCOME

Specialized in R&D and production of recombinant protein drugs, and committed to providing better solutions for viral hepatitis, malignant tumor and immunotherapy etc..

Fax: +86-592-6889110
international@amoytop.com
Tel: +86-592-6889106

Leave a Message